Ashina, MessoudMessoudAshinaMitsikostas, Dimos DDimos DMitsikostasAmin, Faisal MohammadFaisal MohammadAminKokturk, PinarPinarKokturkSchankin, Christoph JosefChristoph JosefSchankinSahin, GurdalGurdalSahinPozo-Rosich, PatriciaPatriciaPozo-RosichDorman, Paul JPaul JDormanNežádal, TomášTomášNežádalPoole, Anne ChristineAnne ChristinePooleMartins, Isabel PavãoIsabel PavãoMartinsSumelahti, Marja-LiisaMarja-LiisaSumelahtiRamirez Campos, VerenaVerenaRamirez CamposAhn, Andrew HAndrew HAhnLyras, LeonidasLeonidasLyrasTassorelli, CristinaCristinaTassorelli2024-10-252024-10-252023-11https://boris-portal.unibe.ch/handle/20.500.12422/171619BACKGROUND The ongoing Pan-European Real Life (PEARL) phase 4 study is evaluating fremanezumab effectiveness and safety for the prevention of episodic and chronic migraine. This interim analysis reports primary, secondary and exploratory endpoints from when 500 participants completed at least six months of treatment. METHODS Adults with episodic migraine or chronic migraine maintaining daily headache diaries were enrolled upon initiation of fremanezumab. Primary endpoint: proportion of participants with ≥50% reduction in monthly migraine days during the six-month period after fremanezumab initiation. Secondary endpoints: mean change from baseline across months 1-12 in monthly migraine days, acute migraine medication use, and headache-related disability. Exploratory endpoint: mean change in headache severity from baseline across months 1-12. Safety was assessed through adverse events reported. RESULTS Overall, 897 participants were enrolled and 574 included in the effectiveness analyses (episodic migraine, 25.8%; chronic migraine, 74.2%). Of participants with data available, 175/313 (55.9%) achieved ≥50% monthly migraine days reduction during the six-month period post-initiation. Across months 1-12, there were sustained reductions in mean monthly migraine days, acute medication use, disability scores, and headache severity. Few adverse events were reported. CONCLUSION PEARL interim results support the effectiveness and safety of fremanezumab for migraine prevention in a real-world population across several European countries.Trial registration: encepp.eu: EUPAS35111.enCalcitonin gene-related peptide chronic episodic real-world data real-world evidence600 - Technology::610 - Medicine & healtharticle10.48350/1892523798764110.1177/03331024231214987